Takeda Rare Disorders Digest
Claim This Podcastby Takeda
Podcast Overview
<p>Rare Disorders Digest is a Takeda podcast series designed to inform the audience about different rare diseases, and help them understand current diagnostic and treatment modalities, and some of the challenges that clinicians and patients face today.</p> <p>Listeners will hear from medical experts and patient advocates as they share their insights into current care and describe their aspirations for the future.</p> <p><strong>Disclosures:</strong></p> <p>This podcast is made in partnership with Takeda Pharmaceuticals (Asia Pacific) Pte. Ltd., with the registered office 8 Marina Boulevard #05-02, Marina Bay Financial Centre, Tower 1, Singapore 018981.</p> <p>This information is available to the public for information purposes only; it should not be used for diagnosing or treating a health problem or disease. It is not intended to substitute consultation with a healthcare provider. Please consult your healthcare provider for advice.</p> <p>Intended for a general audience outside the US and UK.</p>
Language
🇺🇲
Publishing Since
12/7/2022
1 verified contact email on file for Takeda Rare Disorders Digest
Pitch yourself as a guest, propose sponsorships, or reach out directly to the host.
Recent Episodes
December 7, 2022
Episode 3 – Clinical experience and challenges with treating post-transplant CMV infection
<p>We head to the clinic this week to hear about Prof. Joe Sasadeusz’s clinical experiences with treating CMV, and the common challenges faced when managing patients with CMV infections. Learn about considerations when selecting between prophylactic and preemptive therapy for patients with CMV infections.</p><p>See <a href="https://omnystudio.com/listener">omnystudio.com/listener</a> for privacy information.</p>
December 7, 2022
Episode 2 – Diagnosis and Treatment of Post-Transplant CMV infection
<p>We chat with Prof. Joe Sasadeusz about current and upcoming approaches to diagnose and treat CMV infections. Prof. Sasadeusz also shares his thoughts on the strengths and limitations of current prophylactic and preemptive treatment strategies and gives us a glimpse into the future of CMV treatment.</p><p>See <a href="https://omnystudio.com/listener">omnystudio.com/listener</a> for privacy information.</p>
December 7, 2022
Episode 1 - Living with a lifelong Cytomegalovirus (CMV) infection
<p>CMV is a common and yet permanent infection that poses risks to people with weakened immune systems. In this episode, Prof. Joe Sasadeusz sets the scene by giving an overview of these infections alongside patient advocate, Ms Lisa Foster.</p> <p>CMV infections have serious consequences, especially those in high-risk groups, such as those with AIDS, and patients who are receiving immunosuppressants following a solid organ (SOT) or hematopoietic stem cell transplant (HSCT).</p><p>See <a href="https://omnystudio.com/listener">omnystudio.com/listener</a> for privacy information.</p>
10 total episodes available
Deep-dive analytics for Takeda Rare Disorders Digest
Frequently asked questions
Have a different question and can't find the answer you're looking for? Reach out to our support team by sending us an email and we'll get back to you as soon as we can.
- What is Takeda Rare Disorders Digest?
<p>Rare Disorders Digest is a Takeda podcast series designed to inform the audience about different rare diseases, and help them understand current diagnostic and treatment modalities, and some of the challenges that clinicians and patients face today.</p> <p>Listeners will hear from medical experts and patient advocates as they share their insights into current care and describe their aspirations for the future.</p> <p><strong>Disclosures:</strong></p> <p>This podcast is made in partnership with Takeda Pharmaceuticals (Asia Pacific) Pte. Ltd., with the registered office 8 Marina Boulevard #05-02, Marina Bay Financial Centre, Tower 1, Singapore 018981.</p> <p>This information is available to the public for information purposes only; it should not be used for diagnosing or treating a health problem or disease. It is not intended to substitute consultation with a healthcare provider. Please consult your healthcare provider for advice.</p> <p>Intended for a general audience outside the US and UK.</p> - How often does this podcast release new episodes?
This podcast updates daily.
- Where can I listen to this podcast?
This podcast is available on 4 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.
- Does this podcast accept guests?
Yes, this podcast regularly features guests.
Legal Disclaimer
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at hey@podengine.ai for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.